Latest News and Press Releases

Growth of 14% for new U.S. TYMLOS® patients in Q1, 2021 vs. Q4, 2020Q1, 2021 TYMLOS net revenue impacted by seasonality and distribution channel destockingApril, 2021 month-to-date new patient adds...

BOSTON, April 20, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Friday, May 7, 2021. The Company will host a...

Regulatory success achieved in Japan by partner Teijin Pharma LimitedOstabaro® approved for treatment of male & female OP patients at high risk of fractureJapan is currently the largest anabolic...

Repurchases $112.2 million of principal amount of the 3.00% convertible notes due September 1, 2024 (“2024 Notes”), representing approximately 37% of the outstanding 2024 NotesEstimated excess cash...

Full year 2020 TYMLOS® U.S. net sales of $208 million was year-over-year growth of 20%Q4 2020 TYMLOS U.S. net sales: $60 million was 8% growth vs. Q4 2019 and 19% growth vs. Q3 2020New patient starts:...

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it will provide a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at...

BOSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter financial results on Thursday, February 25, 2021. The Company will host...

17% growth in January 2021 for new TYMLOS® patients vs. previous 4 month trailing averageHistomorphometry study published: Journal of Bone & Mineral Research in January 2021Cardiovascular safety...

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Kelly Martin, President and CEO will present a virtual corporate update at the 39th Annual J.P....

RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseasesPrader-Willi syndrome (“PWS”) will be the initial...